Clinical Trial Update: The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease [Phase 1, Phase 2]

View source ↗

Summary

This document reports that the Phase 1/2 clinical trial of NouvNeu001 for Parkinson's disease is currently recruiting and evaluating safety, tolerability, and e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• NouvNeu001

Snippet

Sponsor: iRegene Therapeutics Co., Ltd. | Conditions: Parkinson Disease | Phase 1, Phase 2 | Status: RECRUITING